A Study of Molecular Subtypes (Profile) of Colorectal Cancer and Their Correlation with Clinical and Pathological Profile in a Tertiary Care Center in India

Abstract

Background

Colorectal cancer (CRC) is a heterogeneous disease morphologically, histologically, and molecularly. Most of the studies are on this molecular heterogeneity and their clinicopathological correlation from the western world. Very few studies have been done in India.

Objectives

The aims of this study were to evaluate the clinical and pathological profile of CRCs, to determine the frequency of molecular subtypes of CRCs, to correlate between the molecular subtypes and their clinicopathological features, and to determine the association between different molecular subtypes of CRC.

Materials and Methods

A prospective noninvasive interventional study was done on 50 patients (both outpatients and inpatients) with newly diagnosed CRCs presenting to the Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, from February 2019 to March 2020. Clinical and histopathological data were collected from case sheets as per the study proforma: history and physical examination, noninvasive and invasive imaging, and histopathological reports. Patients in whom tissue was insufficient or not available for testing for at least three of five molecular markers (KRAS, NRAS, BRAF, MSI, and MLH1 methylation) were excluded. The results were analyzed with SSPS 23.0 software. For comparison of the frequencies among groups, the chi-squared test and the Fisher exact test were used. A p-value of less than 0.05 was considered statistically significant.

Results

The median age was 53 years. The majority of the males (54%) had CRC and 44% were right-sided colon tumors. Of the 50 patients with CRC, 40, 0, 4, and 4% had KRAS mutation, NRAS and BRAF mutation, and deficient mismatch repair (dMMR), respectively. KRAS mutation was significantly associated with upfront liver metastases (p = 0.02) and well/moderate differentiation (p = 0.02). BRAF wild-type tumors were likely to be well differentiated (p = 0.02), and moreover, half of them (52%) had MLH1 promoter methylation. The proportion of dMMR was higher in male patients (p = 0.04). Deficient mismatch repair was associated with well/moderate differentiation (p = 0.02), early stage (p =0.02), and mild peritumoral lymphocytes (p = 0.01). None of the dMMR patients had stage IV CRC. In all, 27% of the patients (3/11) with dMMR tumors had germline mutation of the dMMR genes. The majority of dMMR tumors (43%, 3 out of 7) had MLH1 promoter methylation. Overall, 45% (5/11) of dMMR tumors harbored KRAS mutation.

Conclusion

In conclusion, this is a prospective study evaluating the correlations between RAS/BRAF mutation and dMMR status with clinicopathological characteristics in Indian CRC patients, which is slightly similar to worldwide reports with some exceptions. To the best of our knowledge, this is the first study to evaluate the molecular marker combinations in CRC in India.

Keywords

clinical - colorectal cancer - correlation - India - molecular subtypes - pathological - profile

Previous Presentation

The abstract of the study was presented as poster at WGI–ESMO 2022 in Barcelona, Spain.

Ethical Approval

The study was approved by the Ethics committee of the Rajiv Gandhi Cancer Institute and Research Centre.

Publikationsverlauf

Eingereicht: 10. Oktober 2023

Angenommen: 28. November 2024

Artikel online veröffentlicht:
31. Januar 2025

• References

• 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
• 2 Yamauchi M, Lochhead P, Morikawa T. et al. Colorectal cancer: a tale of two sides or a continuum?. Gut 2012; 61 (06) 794-797
• 3 Yamauchi M, Morikawa T, Kuchiba A. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61 (06) 847-854
• 4 Li X, Yao X, Wang Y. et al. MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features. PLoS One 2013; 8 (03) e59064
• 5 Zhang X, Ran W, Wu J. et al. Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China. PeerJ 2018; 6: e4341
• 6 Nagasaka T, Sasamoto H, Notohara K. et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22 (22) 4584-4594
• 7 Koinuma K, Shitoh K, Miyakura Y. et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004; 108 (02) 237-242
• 8 Domingo E, Laiho P, Ollikainen M. et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41 (09) 664-668
• 9 McGivern A, Wynter CVA, Whitehall VLJ. et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004; 3 (02) 101-107
• 10 Charlton ME, Kahl AR, Greenbaum AA. et al. KRAS testing, tumor location, and survival in patients with stage IV colorectal cancer: SEER, 2010–2013. J Natl Compr Canc Netw 2017; 15 (12) 1484-1493
• 11 Nakanishi R, Harada J, Tuul M. et al. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol 2013; 18 (06) 1042-1048
• 12 Zhu XL, Cai X, Zhang L. et al. KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese. Zhonghua Bing Li Xue Za Zhi 2012; 41 (09) 584-589
• 13 Veldore VH, Rao MR, Prabhudesai SA. et al. Prevalence of KRAS mutations in metastatic colorectal cancer: a retrospective observational study from India. Indian J Cancer 2014; 51 (04) 531-537
• 14 Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol 2014; 31 (09) 124
• 15 Irahara N, Baba Y, Nosho K. et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010; 19 (03) 157-163
• 16 Li W, Qiu T, Zhi W. et al. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 2015; 15: 340
• 17 Nayak SS, Roy P, Arora N. et al. Prevalence estimation of microsatellite instability in colorectal cancers using tissue microarray based methods: a tertiary care center experience. Indian J Pathol Microbiol 2018; 61 (04) 520-525
• 18 Samowitz WS, Albertsen H, Sweeney C. et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98 (23) 1731-1738
• 19 Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10 (04) 293-300
• 20 Berg M, Danielsen SA, Ahlquist T. et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PloS One 2010; 5 (11) e13978
• 21 Hampel H, Frankel WL, Martin E. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352 (18) 1851-1860
• 22 Chika N, Eguchi H, Kumamoto K. et al. Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol 2017; 47 (02) 10 PubMed
• 23 Ye J-X, Liu Y, Qin Y, Zhong H-H, Yi W-N, Shi X-Y. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol 2015; 21 (05) 1595-1605
• 24 Nash GM, Gimbel M, Cohen AM. et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 2010; 17 (02) 416-424